Overview

Study of NSI-189 for Major Depressive Disorder

Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The study will consist of a screening period and a randomized treatment. Approximately 220 subjects who meet eligibility during the screening period will be randomized to initiate a 12-week, double-blind treatment with NSI-189 80 milligrams/day (provided as 40 milligrams twice per day), NSI-189 40 milligrams once a day, or placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Neuralstem Inc.